Graymatters
GrayMatters is the first to create a non-invasive digital-therapy device that harnesses brain plasticity to treat PTSD. . Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD14—20m (Dealroom.co estimates Mar 2023.)
Company register number 515916781
Haifa Haifa District (HQ)
Financials
Estimates*
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 1.5m | 2.4m |
| % growth | - | 60 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$3.5m | Seed | ||
* | €2.5m | Grant | |
* | $10.0m | Series A | |
N/A | Support Program | ||
€2.0m | Early VC | ||
| Total Funding | AUD28.5m | ||
Related Content
Recent News about Graymatters
EditMore about Graymatters
EditDeveloper of digital therapeutics designed to cure mental illness. The company's digital therapeutics follow the self-regulation of brain processes to solve the issues related to mental health and neurologic disorder, enabling patients suffering from neurological disorders to treat their diseases in a hassle-free manner.
Keywords: Pharmaceuticals and Biotechnology, Digital Therapeutics, Digital Therapeutics Software, Digital Therapy Platform, Eeg Biomarkers, Eeg Device, Eeg Equipment Software, Fmri Analysis, Healthcare Therapeutics Company, Machine Learning Technology, Therapeutics Device.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.